Treating CLL Patients who Harbor the 17p Deletion
William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with CLL who harbor the 17p deletion.
William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with CLL who harbor the 17p deletion.
Clinical Pearls:
- CLL patients who have a 17p deletion and have been previously treated are at the highest risk
- Untreated patients experience a short first remission following standard treatment
- Untreated patients could benefit from frontline ibrutinib, as early data have shown that ibrutinib improves the survival of relapsed patients
- There is no standard treatment for patients with 17p deletion​
Recent Videos
Related Content
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025Article
The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
